用于肿瘤标志物发现的中等长度非编码RNA随机引物高通量测序方法开发与比较OA
Development and comparison of a random-primer high-throughput sequencing method for mid-sized non-coding RNA biomarker discovery in cancer
目的 精准外科与肿瘤个体化治疗越来越依赖能够反映肿瘤分子分型、复发风险及治疗反应的生物标志物.中等长度非编码RNA(mid-sized non-coding RNA,mncRNA)参与核糖体生物发生、RNA加工和选择性翻译,并在多种肿瘤中与恶性进展及治疗应答相关,具有成为新型肿瘤标志物的潜力.然而,mncRNA复杂的二级结构、碱基修饰和末端形式使其检测易受建库策略影响,限制了相关标志物的系统发现.本研究针对结构化mncRNA的检测难点,自主开发随机引物-DNA接头连接测序方法,并与两种常用建库策略进行比较,评价其在肿瘤mncRNA标志物发现中的技术性能.方法 以HeLa细胞作为肿瘤细胞模型,分别采用RNA接头连接法、Poly(A)加尾-模板转换法以及本研究自主开发的随机引物-DNA接头连接法(以下简称随机引物法)进行RNA测序,并从完整RNA读段比例、长度分布和RNA类型组成等方面进行比较.随机引物法在RNA 3′端连接接头后,采用带随机碱基的RT引物和SuperScript IV进行逆转录,并在cDNA端连接DNA接头完成文库构建.结果 三种策略呈现明显的技术偏倚.RNA接头连接法完整读段比例最低;poly(A)加尾-模板转换法有所改善,但以短片段为主;随机引物法完整RNA读段比例最高(约40%),且明显提高了对tRNA相关序列的检出能力.三种方法均可检出rRNA、snoRNA、tRNA、snRNA和miRNA等多类mncRNA,且不同建库策略对不同RNA类型呈现明显偏好,提示建库方法可直接影响候选肿瘤标志物的发现范围.结论 本研究自主开发的随机引物法在完整RNA及tRNA/tsRNA覆盖方面显示出优势,可为结构复杂、修饰丰富的mncRNA及相关候选肿瘤标志物的发现提供新的技术选择.本研究采用HeLa细胞进行方法学验证,所建立的方法仍需进一步在不同实体瘤的手术切除组织及血液等临床样本中验证其跨癌种适用性,并评估其发现与肿瘤分型、复发风险、预后和治疗反应相关标志物的能力.
Objective Precision surgery and individualized cancer treatment increasingly rely on molecular biomarkers that inform tumor classification,recurrence risk,prognosis,and therapeutic response.Mid-sized non-coding RNAs(mncRNAs)participate in ribosome biogenesis,RNA processing,and selective translation and have been associated with malignant progression and treatment response in multiple cancers,suggesting their potential as a source of novel tumor biomarkers.However,the complex secondary structures,nucleotide modifications,and diverse terminal configurations of mncRNAs make their detection highly susceptible to library-preparation bias,limiting systematic biomarker discovery.To address these challenges,we developed a random-primer DNA-adapter ligation sequencing method and compared it with two commonly used library-preparation strategies to evaluate its technical performance for mncRNA biomarker discovery in cancer.Methods HeLa cells were used as a tumor cell model and profiled using RNA-adapter ligation,poly(A)-tailing/template-switching,and the random-primer DNA-adapter ligation methods developed in this study.In the random-primer methods,an RNA adapter was ligated to the RNA 3′ end,followed by reverse transcription using a random-sequence-containing RT primer and SuperScript IV,and subsequent ligation of a DNA adapter to the cDNA.The resulting datas-ets were compared in terms of full-length RNA recovery,RNA length distribution,and RNA biotype composition.Results The three strategies exhibited distinct technical biases.RNA-adapter ligation yielded the lowest proportion of full-length RNA reads.Poly(A)-tailing/template-switching improved full-length RNA recovery to some extent but predominantly generated shorter RNA fragments.In contrast,the random-primer methods achieved the highest proportion of full-length RNA reads(approximately 40%)and substantially enhanced the detection of tRNA-related sequences.All three approaches detected diverse classes of mncRNAs,including rRNAs,snoRNAs,tRNAs,snRNAs,and miRNAs,while show-ing clear preferences for specific RNA biotypes,indicating that library preparation can directly influence the spectrum of candidate tumor biomarkers identified.Conclusion The random-primer methods devel-oped in this study showed advantages in recovering full-length RNAs and achieving broader coverage of tRNAs/tsRNAs,providing a new technical option for discovery-oriented studies of structurally complex and extensively modified mncRNAs.The method was validated using HeLa cells and should be further evaluated in surgical tumor specimens and blood-based samples from different solid tumors to establish its cross-cancer applicability and its ability to identify biomarkers associated with molecular stratifica-tion,recurrence,prognosis,and therapeutic response.
李好;张曼;邓锦思;占子凌;廖建友;郑琤
中山大学孙逸仙纪念医院基础与转化医学研究中心,广州 510120中山大学孙逸仙纪念医院基础与转化医学研究中心,广州 510120中山大学孙逸仙纪念医院基础与转化医学研究中心,广州 510120中山大学孙逸仙纪念医院基础与转化医学研究中心,广州 510120中山大学孙逸仙纪念医院基础与转化医学研究中心,广州 510120中山大学孙逸仙纪念医院基础与转化医学研究中心,广州 510120
医药卫生
肿瘤中等长度非编码RNA高通量测序分子标志物精准诊疗
cancermid-sized non-coding RNAhigh-throughput sequencingmolecular bio-markerprecision medicine
《岭南现代临床外科》 2026 (4)
265-272,8
国家自然科学基金面上项目(82273033)
评论